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pidemic of diabetes, affecting about
3–5%ofWesternpopulations,isone
of the main threats to human health
in the 21st century (1). Changes in the
human environment, behavior, and life-
style have resulted in a dramatic increase
in the incidence and prevalence of diabe-
tesinpeoplewithgeneticsusceptibilityto
diabetes. The global number of people
with diabetes was 151 million in 2000,
and it is projected to increase to 221 mil-
lion in 2010 (an increase of 46%) both in
developed and developing countries (2).
Chronichyperglycemialeadstomany
long-term complications in the eyes, kid-
neys, nerves, heart, and blood vessels. In-
dividuals with pre-diabetes, undiagnosed
type 2 diabetes, and long-lasting type 2
diabetes are at high risk of all complica-
tions of macrovascular disease, coronary
heart disease (CHD), stroke, and periph-
eral vascular disease. More than 70% of
patients with type 2 diabetes die of car-
diovascular causes (3). Therefore, the ep-
idemic of type 2 diabetes will be followed
byanepidemicofdiabetes-relatedcardio-
vascular disease (CVD).
Over the years, epidemiological stud-
ies have produced important information
on the prevalence and incidence of diabe-
tes complications in different popula-
tions. They have also given important
information on different risk factors de-
termining susceptibility to diabetes com-
plications (Fig. 1). This information is
crucialformechanisticstudiesinphysiol-
ogy at the tissue level and for molecular
biology studies at the cellular level. A
good example is glycated hemoglobin.
Several studies have indicated that gly-
cated hemoglobin is associated with dia-
betes complications in prospective
epidemiological studies. That informa-
tion has been crucial for the planning of
clinical trials to test the hypothesis that
the treatment of chronic hyperglycemia
leads to reduction in long-term diabetes
complications. Moreover, information
from epidemiology has led to several
mechanisticstudiesandtheelucidationof
molecularlevelinsightshowinsulinresis-
tance and hyperglycemia lead to diabetes
complications.
Deﬁning the problem: type 2
diabetes and pre-diabetes increase
the risk of CVD
The risk of CVD mortality in type 2 dia-
betic patients is more than double com-
pared with that in age-matched subjects.
Stroke events and all manifestations of
CHD,myocardialinfarction(MI),sudden
death, and angina pectoris are at least
twofold more common in patients with
type 2 diabetes than in nondiabetic indi-
viduals (4). A high proportion of patients
with type 2 diabetes die after an acute MI
within 1 year, and a considerable number
of patients die outside the hospital (5).
Relative risk for CHD events is higher in
female patients with type 2 diabetes than
in male patients with type 2 diabetes. The
reason for the sex difference is largely un-
known but could be at least in part ex-
plained by a heavier risk-factor burden
and a greater effect of blood pressure and
atherogenic dyslipidemia on the risk of
CVD in diabetic women than in diabetic
men (6).
The prognosis of patients with type 2
diabetes is highly dependent on the pres-
ence of CVD. We compared the 7-year
incidence of fatal and nonfatal MI among
1,373 nondiabetic subjects with the inci-
dence among 1,059 subjects with type 2
diabetes(7).Ourstudysuggestedthatpa-
tients with type 2 diabetes without previ-
ous MI have as high a risk of MI as
nondiabetic patients with previous MI.
Thus, our results indicated that type 2 di-
abetes is a “coronary heart disease equiv-
alent.” These results were recently
replicatedbya18-yearfollow-upstudyof
our original cohort (8) (Fig. 2) and by a
Danish study including 3.3 million sub-
jects (9).
Oneoftheparadoxesinthestudiesof
cardiovascularcomplicationsintype2di-
abetesisthatatdiagnosisindividualswith
type 2 diabetes already have substantially
increased prevalence of CHD and stroke
(4). Although a part of this risk could be
attributed to asymptomatic hyperglyce-
mia, fulﬁlling the criteria for diabetes
years before diagnosis, it is unlikely that
this could explain the increased risk of
CVD because duration of diabetes is not a
verystrongriskfactorforCVDinsubjects
with type 2 diabetes. In agreement with
these results are the ﬁndings from the UK
Prospective Diabetes Study (UKPDS)
(10). At low glycated hemoglobin levels,
even in the normal range, the risk of
CHD events was substantially increased
comparedwiththeriskofretinopathy,in-
dicating that risk factors other than hy-
perglycemia must explain increased CHD
events.Studiesinpre-diabeticindividuals
give further evidence. Several studies
show that subjects with impaired glucose
tolerance (IGT, 2-h plasma glucose levels
7.8–11.0 mmol/l) or impaired fasting
glucose (IFG, plasma glucose 5.6–6.9
mmol/l) have about twofold higher risk
for CVD events than normoglycemic sub-
jects (11).
The Whitehall study was the ﬁrst to
show an increased risk of CVD when the
2-h level exceeded 5.5 mmol/l (12). A
meta-analysis of 20 studies including
95,783 nondiabetic individuals followed
for 12.4 years showed that high fasting,
1-h, and 2-h glucose levels increased the
risk for CVD events (11). The DECODE
(Diabetes Epidemiology: Collaborative
analysis of Diagnostic criteria in Europe)
study analyzed 10 prospective European
cohort studies including 15,388 men and
7,126 women (13). The relationship be-
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ready was observed within the normal
glucose range and exhibited a linear rela-
tionship without any indication of a
threshold effect.
Pre-diabetes—key for the
understanding of cardiovascular
complications in type 2 diabetes
Impaired insulin action (insulin re-
sistance) in combination with impaired
insulin secretion is a major pathophysio-
logical mechanism leading to elevated
fasting or postprandial glucose in pre-
diabetic individuals. Impaired insulin
action is observed in several tissues,
particularly in skeletal muscle, adipose
tissue, endothelium, and the liver. Com-
pensatory hyperinsulinemia is often seen
in pre-diabetic individuals because the
pancreas compensates for insulin resis-
tance in peripheral insulin-sensitive
tissues.
Pre-diabetes is a heterogeneous en-
tity. Both IFG and IGT are characterized
byinsulinresistance.Previoussmallstud-
ies demonstrated that individuals with
IGT have a more pronounced degree of
insulin resistance, whereas individuals
withIFGarecharacterizedbyamorepro-
nounced -cell defect when related to the
ambient glucose levels and the degree of
insulin sensitivity (14,15). We recently
carried out a study including almost
1,000offspringoftype2diabeticpatients
and showed that participants with iso-
lated IFG had impaired basal insulin se-
cretion, reduced ﬁrst-phase insulin
response, and reduced insulin sensitivity
compared with normoglycemic individu-
als (16). Subjects with IFG also have re-
duced hepatic sensitivity to insulin (17).
In contrast, a characteristic ﬁnding in
subjects with isolated IGT is increased in-
sulin resistance (16).
Several studies have provided evi-
dence that high insulin level is associated
with risk of CHD in nondiabetic subjects
in prospective population studies (sum-
marized in 18). We were the ﬁrst to show
that insulin resistance per se is directly
associated with atherosclerosis, even in
normoglycemic subjects. We measured
insulin sensitivity by the euglycemic-
hyperinsulinemic clamp and asymptom-
atic atherosclerosis with ultrasound
method in the femoral or carotid arteries
(19). Healthy nonobese subjects without
any medication but who had atheroscle-
rotic plaques and corresponding control
subjects without signs of atherosclerosis
were included in the study. Subjects with
asymptomatic atherosclerosis exhibited
an approximate 20% decrease in insulin-
mediated glucose. Our study provides
evidence that the primary events respon-
sible for atherothrombosis could be re-
lated to insulin resistance per se.
Changes in cardiovascular risk
factors in pre-diabetes and type 2
diabetes
Mechanisms linking pre-diabetes and
type 2 diabetes with CVD remain poorly
understood. Both of these conditions
share insulin resistance in several tissues,
and when frank hyperglycemia develops
thereareseveralpotentialmechanismsfor
high glucose to increase the risk of
atherothombosis (20). Pre-diabetic sub-
jects often have a clustering of different
CVD risk factors, insulin resistance, obe-
sity, central obesity, elevated blood pres-
sure, elevated total triglycerides, and low
HDL cholesterol. Therefore, it is unclear
whether hyperglycemia per se in the
nondiabetic range is causally associated
with the risk of CVD. Type 2 diabetic pa-
tients are at least as insulin resistant as
pre-diabetic subjects. Therefore, insulin
resistance–related risk factors in the
pre-diabetic state and insulin resistance–
related and hyperglycemia–related risk
factors in type 2 diabetes are likely to ex-
plain a major part of enhanced athero-
thrombosis in these conditions (Fig. 3).
Metabolic changes in pre-diabetes in-
cludeimpairedendothelialfunction,sub-
clinical inﬂammation (21), changes in
adipokines, development of atherogenic
dyslipidemia, increased levels of free fatty
acids (FFAs), and changes in thrombosis
and ﬁbrinolysis (22).
Impaired endothelial function
The earliest ﬁnding in the pathogenesis of
atherosclerotic lesions is impaired endo-
thelial function, which is tightly linked to
insulin resistance. We demonstrated that
insulin-stimulated increase in leg glucose
disposalandbloodﬂowwerecoupledina
dose-dependent manner (23,24). The va-
Figure 1—Different approaches in studies of cardiovascular complications in type 2 diabetes.
Figure 2—Incidence per 1,000 person-years and Cox model hazard ratio for CHD death (ad-
justed for age, area of residence, and sex) during the 18-year follow-up according to the presence
ofdiabetesandpriorevidenceofMIin1,373nondiabeticand1,059diabeticsubjects.Adaptedfrom
ref. 8.
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on nitric oxide (NO) generation, since
blocking insulin-induced increases in
blood ﬂow with NO synthase inhibitor
N
G-monomethyl-L-arginine diminished
both blood ﬂow and glucose uptake (25).
Thus, vascular actions of insulin control
its delivery to muscle and regulate the
rate-limiting step in skeletal muscle insu-
lin action (26). Indeed, NO-dependent
increases in blood ﬂow to skeletal muscle
could account for 25 to 40% of the in-
crease in glucose uptake in response to
insulin stimulation (27).
As shown in Fig. 4 phosphatidylinosi-
tol 3-kinase (PI 3-kinase)-dependent
insulin signaling pathways in the endothe-
lium related to the production of NO share
striking similarities with metabolic path-
ways in skeletal muscle that promote glu-
cose uptake. Insulin-stimulated glucose
uptake requires PI 3-kinase–dependent
signaling pathways that involve insulin re-
ceptor substrate 1 (IRS-1), PI 3-kinase,
phosphoinositide-dependent kinase 1
(PDK-1), Akt, and downstream effectors to
contribute to insulin-stimulated transloca-
tion of insulin-responsive GLUT4. PI 3-
kinase activation is necessary but not
sufﬁcientforinsulin-stimulatedproduction
of NO, resulting in vasodilatation. Shc/Ras/
mitogen-activated protein (MAP) kinase
pathway is a distinct nonmetabolic branch
of the insulin-signaling pathway regulating
secretion of the vasoconstrictor endothe-
lin-1, one of the most potent vasoconstric-
tors, and vascular cell adhesion molecule 1
(VCAM-1) in endothelium as well as
growth and mitogenesis. Metabolic insulin
resistance is characterized by pathway-
speciﬁc impairment in PI 3-kinase–
dependent signaling induced, e.g., by
proinﬂammatory cytokines (tumor necro-
sis-[TNF-],interleukin[IL]-1,IL-6,C-
reactive protein [CRP]), which in the
endotheliummaycauseimbalancebetween
production of NO and glucose uptake, re-
sulting in insulin resistance and endothelial
dysfunction.
Hyperglycemiainhibitsproductionof
NO, leads to elevated FFA levels due to
impairment in insulin’s antilipolytic ef-
fect,andincreasestheproductionofreac-
tive oxygen species, contributing to the
reduction of NO synthesis (28). Hyper-
glycemia also increases the production of
endothelin-1 (27). In addition, diabetes
leads to abnormal vascular smooth mus-
cle cell function due to impaired NO-
mediated vasodilation, increased levels
of endothelin-1, angiotensin II, and plas-
minogen activator inhibitor 1 (PAI-1)
(29). Therefore, in hyperglycemia the PI
3-kinase pathway is even more down-
regulated and the Shc/Ras/MAP-kinase
pathway even more upregulated than in
the pre-diabetic state.
Subclinical inﬂammation
Low-grade inﬂammation is linked to in-
sulin resistance and is involved in the
pathogenesis of type 2 diabetes (30). In-
ﬂammatory and insulin signaling path-
ways are tightly linked, both of which
lead to insulin resistance and endothelial
dysfunction,contributingtocardiovascu-
lar complications. Adipose tissue is an ac-
tive endocrine and paracrine organ that
releases a large number of cytokines and
bioactive mediators, such as leptin, adi-
ponectin,IL-6,andTNF-,thatinﬂuence
insulinresistance,inﬂammation,andath-
erosclerosis (31). Obesity is also associ-
ated with more generalized, systemic
inﬂammation involving circulating in-
ﬂammatory proteins such as CRP, IL-6,
PAI-1, P-selectin, VCAM-1, and ﬁbrino-
gen. Adhesion molecule expression is in-
duced by proinﬂammatory cytokines
suchasIL-1,TNF-,andCRPproduced
by the liver in response to IL-6 (32).
Our study in offspring of subjects of
patients with type 2 diabetes who are at
high risk of developing diabetes and CVD
demonstrated the presence of insulin re-
sistance, an excess of intra-abdominal fat
mass, hypoadiponectinemia, and multi-
ple defects in glucose and energy metab-
olism in these individuals (33). We also
found high levels of high-sensitivity CRP
(hs-CRP), IL-6, IL-1, IL-1 receptor an-
tagonist, and adhesion molecules (P-
selectin, intracellular adhesion molecule
1, ICAM-1) among these pre-diabetic
subjects, indicating that low-grade in-
ﬂammation and markers of endothelial
dysfunction are characteristic ﬁndings in
Figure 3—Relative risk of CVD in normoglycemia, pre-diabetes, and type 2 diabetes.
Figure 4—Parallel insulin-signaling pathways mediating metabolic and vascular effects in
peripheraltissues.eNOS,endothelialnitricoxidesynthase;ET-1,endothelin1.Modiﬁedfrom
ref. 27.
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CVD (33,34).
Adipokines
Several adipokines, such as leptin, adi-
ponectin, TNF-, IL-6, resistin, visfatin,
and retinol-binding protein 4, have been
suggestedtobeassociatedwithinsulinre-
sistance (31). Adiponectin has important
anti-atherogenic, antidiabetic, and anti-
inﬂammatory properties and is expressed
abundantly in adipocytes. In subjects
with an excess of intra-abdominal fast
mass, adiponectin levels are low, which
might be explained by an increase in
TNF- secretion from visceral fat. High
adiponectin level correlates with high in-
sulin sensitivity (35). Adiponectin inhib-
its the expression of ICAM-1, VCAM-1,
and E-selectin through the inhibition of
nuclear factor-B (NF-B) activation and
has several antiatherogenic and anti-
inﬂammatory properties (35).
Atherogenic dyslipidemia
Insulin resistance and type 2 diabetes are
associated with several changes in lipids
and lipoproteins. We measured insulin
resistance by the euglycemic-hyperinsu-
linemic clamp technique in subjects with
varying degrees of glucose tolerance (36).
Insulin-resistant subjects had higher total
and VLDL triglycerides and lower HDL
cholesterol than subjects with high insu-
lin sensitivity. Elevated levels of triglycer-
ide-rich lipoproteins, either in the fasting
or postprandial state (37), are character-
istic ﬁndings in patients with type 2
diabetes (VLDL, metabolites of VLDL,
chylomicron remnants). Low HDL cho-
lesterol, often associated with high levels
oftotalandVLDLtriglycerides,isanother
characteristic lipid abnormality in pa-
tients with type 2 diabetes (38).
The fundamental defect in lipid me-
tabolism in patients with type 2 diabetes
is the hepatic overproduction of large
VLDL particles, particularly VLDL1 (38).
Overproduction of VLDL particles ini-
tiates a series of other changes in lipopro-
teins, resulting in high levels of remnant
particles, small dense LDL, and low HDL
cholesterol levels. In addition to reduced
levelsofHDLcholesterolandapolipopro-
tein A-I (3), there are abnormalities in
the size and composition of the HDL par-
ticles (38) (decreased particle numbers,
changes in particle composition) in pa-
tients with type 2 diabetes. Reduced con-
centrations of HDL and apolipoprotein
A-I promote the accumulation of choles-
terol in the vessel wall and lead to
atherosclerosis.
Total and LDL cholesterol levels are
usually normal in type 2 diabetic individ-
uals, but compositional changes in LDL
particlesoccur(smalldenseLDL,hightri-
glyceride content, and oxidative modiﬁ-
cation of LDL particles), and the number
ofLDLparticlesisincreased(37).Because
each LDL particle contains one apoli-
poprotein B molecule, patients with type
2 diabetes also have increased levels of
apolipoproteinB.Anincreasednumberof
LDL particles might contribute to athero-
genesis (39). Small dense LDL particles
rapidly enter the arterial wall and can be
toxic to endothelial cells, cause greater
production of procoagulant factors, and
can be oxidized more readily than the
large buoyant particles. VLDL1-triglyceride
level is the major predictor of LDL size in
individualswithorwithouttype2diabetes.
Thrombosis and ﬁbrinolysis
Insulin resistance and diabetes are associ-
ated with prothrombotic risk (coagula-
tion factors VII, XII, and ﬁbrinogen) and
with suppression of ﬁbrinolysis due to el-
evated concentrations of the ﬁbrinolytic
inhibitor PAI-1 (40). In insulin-resistant
states,impairedendothelialfunctionsup-
presses NO production and prostacyclin
synthesis and platelets tend to aggregate.
Hyperglycemia and glycation contribute
tothegenerationofclotthatisresistantto
ﬁbrinolysis (40). Elevated levels of PAI-1
have been shown to be associated with
insulin resistance and type 2 diabetes in-
dependent of obesity and poor glycemic
control (41).
Risk factors predicting CVD in
subjects with type 2
diabetes—classic risk factors
All major risk factors, elevated high total
and LDL cholesterol, low HDL choles-
terol, elevated blood pressure, and smok-
ingaresimilarriskfactorsinpatientswith
type 2 diabetes and nondiabetic individ-
uals (42). However, at every level of risk
factor, diabetic subjects have at least two-
fold higher risk than nondiabetic individ-
uals. This indicates that although classic
risk factors are very important determi-
nants of increased risk of CVD in type 2
diabetic subjects, they do not explain the
higher risk of CVD events in these indi-
viduals. Therefore, to understand excess
risk of CVD in type 2 diabetes, other risk
factors have to be considered.
Markers of impaired endothelial
function
IntheFraminghamOffspringStudy,high
levels of von Willibrand factor (vWF), a
biomarker of endothelial damage and
dysfunction, were associated with in-
creased risk of new-onset CVD over 11
years of follow-up of a community-based
sample (43). In the Hoorn study, markers
of endothelial dysfunction and low-grade
inﬂammation explained 43% of the in-
creaseinCVDmortalityconferredbytype
2 diabetes (44).
Markers of inﬂammation
Previous studies have shown that high
levels of CRP, IL-6, and TNF- predict
type 2 diabetes (45). We measured hs-
CRP in 1,045 subjects with type 2 diabe-
tes. Subjects with hs-CRP 3 mg/l had a
higher risk for CHD death than patients
with hs-CRP 3 mg/l, even after the ad-
justment for confounding factors (46).
Therefore, in our large cohort of type 2
diabeticpatients,hs-CRPwasanindepen-
dent risk factor for CHD deaths. In
another recent study, hs-CRP was inde-
pendently associated with short-term
mortality risk in normoalbuminuric type
2 diabetic individuals and in those with-
out a previous diagnosis of CVD (47).
Insulin resistance
Insulin resistance is a characteristic ab-
normality in glucose metabolism in pa-
tients with pre-diabetes and type 2
diabetes. It often clusters with elevated
blood pressure, obesity, central obesity,
elevated levels of total triglycerides, low
levels of HDL cholesterol, and hemostatic
abnormalities.ThisclusteringofCVDrisk
factors exists in nondiabetic individuals
andpatientswithtype2diabetesandpre-
dicts CHD (48,49). Whether hyperinsu-
linemia itself is a predictor of CVD has
been debated (18). Ruige et al. (50) per-
formedameta-analysisofpublishedstud-
ies and showed that a weak positive
associationwasfoundbetweenhighinsu-
lin levels and CVD events.
Since insulin resistance is clustering
with several other risk factors, conven-
tional statistical methods underestimate
the true signiﬁcance of insulin resistance
in increasing the risk of CVD events.
Therefore, factor analysis that can in-
clude several intercorrelated variables
in the same model has been applied. By
applying factor analysis and principal
component analysis, we showed that
“hyperinsulinemia cluster” (a factor hav-
ing high positive loadings for BMI, trig-
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loading for HDL cholesterol) was predic-
tive of death from CHD in middle-aged
and elderly patients with type 2 diabetes
(49,51).
A recent study applied the Archimedes
model to estimate the proportion of MIs
that would be prevented by maintaining
insulin resistance and other risk factors at
healthy levels (52). Person-speciﬁc data
from the National Health and Nutrition
Examination Survey 1998–2004 were
usedtocreateasimulatedpopulationrep-
resentative of young adults in the U.S. In
young adults, preventing insulin resis-
tance would prevent 42% of MIs. Insulin
resistance was more important than sys-
tolic blood pressure (36%), HDL choles-
terol (31%), LDL cholesterol (16%), and
fastingplasmaglucoseandsmoking(both
9%) in the prevention of MI.
Hyperglycemia
Several prospective population-based
studies including a large number of pa-
tients with type 2 diabetes have shown
that glycemic control is important for the
riskofCVD(53–55).However,thisriskis
not particularly strong for CHD. The
UKPDS (10) and our 7-year follow-up
studyon1,059Finnishpatientswithtype
2 diabetes (53) showed that the most im-
portant risk factors for CHD were classic
risk factors, particularly dyslipidemia
(hightotalandLDLcholesterol,hightotal
triglycerides, and low HDL cholesterol).
However, in both of these studies poor
glycemic control also predicted CHD
events, but the association was much
weaker than for classic risk factors.
Wecomparedtheimpactofhypergly-
cemia on the risk of CVD mortality be-
tween patients with type 1 and type 2
diabetes (56). An increment of 1 unit (%)
of glycated hemoglobin increased CVD
mortalityby52.5%intype1diabeticsub-
jects and by 7.5% in type 2 diabetic sub-
jects. These results are consistent with
previousstudiesindicatingthathypergly-
cemiaisprobablythemostimportantrisk
factor for CVD in type 1 diabetes (57),
whereas in type 2 diabetes classic risk
factors and insulin resistance are more
important risk factors for CVD than
hyperglycemia.
Advanced glycation end products
(AGEs),modiﬁcationproductsformedby
glycationorglycoxidationofproteinsand
lipids,havebeenlinkedtoprematureath-
erosclerosis in patients with diabetes.
However, evidence from prospective
studieshasbeenmissing.Weinvestigated
whether increased serum levels of AGEs
predict total and CVD mortality in a ran-
domsampleof874Finnishdiabeticstudy
participants who were followed for 18
years. AGEs were signiﬁcantly associated
with total and CVD mortality in women
but not in men (58).
Pathophysiology of insulin
resistance– and diabetes-related
CVD
Insulin resistance and diabetes cause ac-
celerated atherosclerosis via several
mechanisms affecting endothelium, vas-
cular wall, smooth muscle cells, and
platelets. Insulin resistance is associated
with impaired vasodilatation, increased
oxidative stress, and high concentration
of FFAs, vasoconstrictors, cellular adhe-
sion molecules, PAI-1, cytokines, and
other mediators of low-grade inﬂamma-
tion and thrombosis formation. Type 2
diabetes further enhances these abnor-
malities and induces multiple adverse
changes in the function and structure of
vessel wall including and excess forma-
tion of AGEs (3).
Initiation of atherosclerosis process
The primary event in the process of ath-
erosclerosis is the accumulation of LDL
cholesterol in the subendothelial matrix
in diabetic and nondiabetic individuals
(37). Small and dense LDL particles are
likely to enhance atherogenesis and CVD
risk in type 2 diabetes. In vitro studies
show that small LDL particles rapidly en-
ter the arterial wall, cause greater produc-
tionofprocoagulantfactors,andaremore
readily oxidized (59). Activation of
NF-B signaling cascade leads to the pro-
duction of E-selectin, ICAM-1 and
VCAM-1, as well as chemoattractant cy-
tokines (37). Increased concentrations of
FFAs may also induce inﬂammation,
worsen insulin resistance, and impair en-
dothelium-dependent vasodilation (25).
Low HDL cholesterol and apolipoprotein
A1 levels are likely to contribute to im-
paired removal of excess cholesterol from
atherosclerotic plaques (60).
Hyperglycemia-induced changes
In experimental models, hyperglycemia
plays a central role in early development
ofatherosclerosisbyenhancingmonocyte
adhesion to endothelial cells (61), by ac-
tivation of NF-B, and by production of
AGEs formed by sustained exposure of
proteins and lipids to hyperglycemia.
Glucose-andAGE-mediatedinhibitionof
NO production by endothelial cells is as-
sociated with impaired endothelial func-
tion (62). High glucose concentrations
canalsostimulatetheproliferationofvas-
cular smooth muscle cells and smooth
musclecellmigrationtotheintima,where
they participate in the formation of a ﬁ-
brous cap.
Acute coronary syndrome is usually
a consequence of a coronary plaque
rupture. Thin ﬁbrous cap, caused by de-
creased collagen production or degrada-
tion of collagen and matrix by proteinases,
andinﬂammation,bothoftenobservedin
type 2 diabetes, increase susceptibility to
plaque rupture (3). Platelet activity and
bloodcoagulabilityareincreasedintype2
diabetes, resulting in enhanced thrombus
formation. Advanced atherosclerotic le-
sions in diabetic patients have reduced
number of vascular muscle cells and
therefore these lesions are more vulnera-
ble for rupture.
Animal models
Animal models are needed to understand
the pathophysiology of atherothrombosis
in type 2 diabetic patients. However, no
mouse model has been available where
theeffectoftype2diabetesonatheroscle-
rosis had been investigated without sig-
niﬁcant concomitant changes in plasma
lipid levels. Therefore, we crossbred two
genetically modiﬁed mouse strains to
achieve a model expressing both athero-
sclerosis and characteristics of type 2
diabetes (63). For atherosclerotic back-
ground we used LDL receptor–deﬁcient
mice synthesizing only apolipoprotein
B100 (LDLR
/ ApoB
100/100). Diabetic
background was obtained from transgenic
mice overexpressing insulin-like growth
factor-II (IGF-II) in pancreatic -cells.
IGF-II transgenic LDLR
/ ApoB
100/100
mice exhibited insulin resistance and hy-
perglycemia compared with hypercholes-
terolemic LDLR
/ ApoB
100/100 controls.
IGF-II/LDLR
/ ApoB
100/100 mice dis-
played signiﬁcantly increased lesion calciﬁ-
cation, which was more related to insulin
resistancethanglucoselevels.Lipidlevelsof
IGF-II/LDLR
/ ApoB
100/100 mice did not
differ from LDLR
/ ApoB
100/100 controls
atanytime.Therefore,inthisanimalmodel
a combination of insulin resistance and hy-
perglycemiainducedincreasedcalciﬁcation
and lesion progression.
Vascular endothelial growth factors
(VEGFs) are potent angiogenic factors
that can affect plaque neovascularization.
Therefore, we determined the effect of di-
abetes on atherosclerosis and expression
Cardiovascular disease in type 2 diabetes
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scleroticlesions(64).Alloxanwasusedto
induce diabetes in male Watanabe herita-
ble hyperlipidemic rabbits. Accelerated
atherogenesis was observed in the dia-
betic rabbits, and atherosclerotic lesions
had an increased content of macrophages
and showed signiﬁcant increases in im-
munostainings for VEGF-A, VEGF-D,
VEGF receptor-1, VEGF receptor-2, re-
ceptor for AGE (RAGE), and NF-B.
These results suggest that diabetes up-
regulates VEGF-A, VEGF-D, and VEGF
receptor-2 expression and increases NF-
B, RAGE, and inﬂammatory responses
in atherosclerotic lesions.
“Common soil” hypothesis of
diabetes complications
Elegant studies of Brownlee et al. (65)
have shown that a single unifying mech-
anism of diabetes complications might be
hyperglycemia-induced overproduction
of superoxide by the mitochondrial elec-
tron transport chain, which activates four
damaging pathways: polyol pathway,
hexosamine pathway, protein kinase C
pathway, and AGE formation. These au-
thors also showed that insulin resistance
induced by high FFA levels caused in-
creased production of superoxide in arte-
rial endothelial cells (66). The FFA-
induced overproduction of superoxide
activates proinﬂammatory signals and
leads to impaired endothelial function.
Our study showed that proliferative
retinopathy predicted CVD and CHD
deathintype2diabeticsubjectswhowere
free of CVD at baseline (67). The associa-
tion of retinopathy with mortality was in-
dependent not only of conventional CVD
risk factors but also of glycemic control
and duration of diabetes. Similar results
havebeenpublishedpreviously(68).Our
results are in agreement with the concept
that similar underlying processes are re-
sponsible for micro- and macrovascular
complications in diabetes.
Diabetic retinopathy and athero-
thrombosis share pathophysiological
similarities. Both processes include im-
paired endothelial function, inﬂamma-
tion, neovascularization, apoptosis, and
the hypercoagulable state. The neovascu-
larization of the vessel wall has been
found to be a consistent feature of the de-
velopment of atherosclerotic plaque, and
vasa vasorum neovascularization pre-
cedes endothelial dysfunction (69). Be-
cause proliferative retinopathy has been a
more important predictor than back-
ground retinopathy in several studies, in-
cluding our study (67), this may imply
that neovascularization is an especially
important common pathway leading to
micro- and macrovascular complications.
Micro- and macrovascular disease in
type 2 diabetes are likely to share com-
monpathways(Fig.5).Bothinsulinresis-
tanceandhyperglycemialeadtooxidative
stress and mitochondrial overproduction
of superoxide and activate damaging
pathways leading to diabetes complica-
tions. The Diabetes Control and Compli-
cationsTrialshowedthatinsulin-resistant
type 1 diabetic patients at their baseline
visitwereatthehighestsubsequentriskof
developing micro- and macrovascular
complications (70). Insulin-resistant dia-
betic patients often have nephropathy,
and a clustering of CVD risk factors that
further accelerate atherothrombosis.
Concluding remarks
Several mechanisms described in this re-
viewcancontributetoacceleratedathero-
thrombosis in patients with type 2
diabetes, but only limited data from pro-
spective population studies are available
to evaluate the signiﬁcance of these po-
tential mechanisms on CVD risk. Direct
proofofthesenewmechanismsidentiﬁed
throughinvitroexperimentsisdifﬁcultto
obtain due to a lack of simple markers
applicable for large epidemiological and
clinical studies.
Recent trials on the prevention of
CVD events by the treatment of hypergly-
cemia in patients with type 2 diabetes
have been disappointing. This is likely to
reﬂect the dominant role of insulin resis-
tance in CDV events in patients with type
2 diabetes. In fact, insulin resistance is
regulating almost all mechanisms known
to be associated with CVD in pre-diabetic
and diabetic subjects. Studies published
so far underestimate the true role of insu-
lin resistance because of the lack of statis-
tical models for the analysis of cross-talk
betweendifferentinsulin-sensitivetissues
and networks of insulin resistance–
related mechanisms. A recent article in-
cluding a mathematical analysis of CVD
risk factors and their interrelated path-
wayshassuggestedamajorroleofinsulin
resistance and obesity as potential causes
for high risk of CVD among diabetic pa-
tients (52). Therefore, more research is
needed to elucidate the mechanisms of
insulin resistance– and hyperglycemia-
related CVD both in pre-diabetic and di-
abetic individuals.
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